ArticleThe Journal of infectious diseases2019
Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal.
Article in The Journal of infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 7 syntheses or guidelines pooled it.
- Automated reporting of primaquine dose efficacy, tolerability and safety for Plasmodium vivax malaria using a systematic review and individual patient data meta-analysis.Malaria journal · 2025Pooled it
- Primaquine for uncomplicated Plasmodium vivax malaria in children younger than 15 years: a systematic review and individual patient data meta-analysis.The Lancet. Child & adolescent health · 2024Pooled it
- Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis.The Lancet. Infectious diseases · 2024Pooled it
- Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.The Lancet. Infectious diseases · 2024Pooled it
- Safety and efficacy of primaquine in patients withBMJ global health · 2023Pooled it
- Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.Malaria journal · 2023Pooled it
- Estimating the Proportion ofThe American journal of tropical medicine and hygiene · 2020Pooled it
- Short-Course Low-Dose Primaquine for Radical Cure in G6PD-Normal Patients in the Pre-Elimination Context of Nepal.Tropical medicine & international health : TM & IH · 2026Trial
- Seven-day versus fourteen-day low-dose primaquine forThe Lancet regional health. Southeast Asia · 2026Article
- Genetic Evidence of Cross-Border Plasmodium vivax Spread in a Malaria Pre-elimination Region of South Asia.The Journal of infectious diseases · 2026Article
- High genetic diversity, clonal activation of hypnozoites and relapse of Plasmodium vivax isolates in low-transmission setting of Ethiopia.Research square · 2026Article
- Haematologic responses to primaquine used for radical cure of Plasmodium vivax in public health facilities in Ethiopia: a prospective observational study.Malaria journal · 2025Observational
- Malaria elimination challenges in countries approaching the last mile: a discussion among regional stakeholders.Malaria journal · 2024Review
- Effectiveness of an Unsupervised Primaquine Regimen for Preventing Plasmodium vivax Malaria Relapses in Northeast Myanmar: A Single-Arm Nonrandomized Observational Study.The Journal of infectious diseases · 2024Observational
- Factors hindering coverage of targeted mass treatment with primaquine in a malarious township of northern Myanmar in 2019-2020.Scientific reports · 2023Article
- Village malaria workers for the community-based management of vivax malaria.The Lancet regional health. Southeast Asia · 2023Review
- Glucose 6 Phosphate Dehydrogenase (G6PD) quantitation using biosensors at the point of first contact: a mixed method study in Cambodia.Malaria journal · 2022Article
- Community engagement for malaria elimination in the Greater Mekong Sub-region: a qualitative study among malaria researchers and policymakers.Malaria journal · 2022Article
- The prevention and treatment of Plasmodium vivax malaria.PLoS medicine · 2021Article
- Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure.PLoS medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPlasmodium vivax is the main cause of malaria in Nepal. Relapse patterns have not been characterized previously.
methodsPatients with P. vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0.25 mg base/kg/day for 14 days) and followed intensively for 1 month, then at 1- to 2-month intervals for 1 year. Parasite isolates were genotyped.
resultsOne hundred and one (49%) patients received CQ and 105 (51%) received CQ + PQ. In the CQ + PQ arm, there were 3 (4.1%) recurrences in the 73 patients who completed 1 year of follow-up compared with 22 of 78 (28.2%) in the CQ-only arm (risk ratio, 0.146 [95% confidence interval, .046-.467]; P < .0001). Microsatellite genotyping showed relatively high P. vivax genetic diversity (mean heterozygosity, 0.843 [range 0.570-0.989] with low multiplicity of infection (mean, 1.05) reflecting a low transmission preelimination setting. Of the 12 genetically homologous relapses, 5 (42%) occurred in a cluster after 9 months, indicating long latency.
conclusionsAlthough there may be emerging CQ resistance, the combination of CQ and the standard-dose 14-day PQ regimen is highly efficacious in providing radical cure of short- and long-latency P. vivax malaria in Nepal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.